NCT01501435View on ClinicalTrials.gov

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Healthy
Interventions
DRUG

CJ-30039

single dose

DRUG

fenofibric acid

single dose

Trial Locations (1)

Unknown

Yonsei university severance hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT01501435 - To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra | Biotech Hunter | Biotech Hunter